Breast Cancer Clinical Trial

Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292).

Summary

A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292).

View Full Description

Full Description

This Phase Ib/III study (CAPItello-292) aims to evaluate the efficacy, safety and the degree of added benefit of capivasertib combined with palbociclib and fulvestrant in participants with endocrine-resistant locally advanced (inoperable) or metastatic HR+/HER2- breast cancer. Although the dosing regimens of capivasertib + fulvestrant and of palbociclib + fulvestrant are established, the dose and schedule for the triplet combination (capivasertib + palbociclib + fulvestrant) needs to be confirmed. Therefore, the initial dose finding Phase Ib part of the study will confirm the recommended Phase III doses (RP3D) and schedule of administration of capivasertib and palbociclib for the triplet combination including fulvestrant which will then be used in the Phase III part of this study.

View Eligibility Criteria

Eligibility Criteria

Key inclusion criteria for both phases:

Adult females (pre- and/or post-menopausal), and adult males.
Histologically confirmed HR+/ HER2- breast cancer determined from the most recent tumour sample (primary or metastatic) per the American Society of Clinical Oncology and College of American Pathologists guideline. To fulfil the requirement of HR+ disease, a breast cancer must express ER with or without co-expression of progesterone receptor.
Eligible for palbociclib and fulvestrant therapy as per investigator assessment. Previous tolerance to specific CDK4/6 inhibitors and dose levels required.
Adequate organ and bone marrow functions.
Consent to provide a mandatory FFPE tumour sample.

Inclusion criteria only for phase III:

Previous treatment with an ET (tamoxifen or an AI) as a single agent or in combination, with:

radiological evidence of breast cancer recurrence or progression while on, or within 12 months of, completing a (neo)adjuvant ET regimen OR
radiological evidence of progression while receiving the ET for locally advanced or metastatic breast cancer (this does not need to be the most recent therapy)
Received up to a maximum of 1 lines of prior chemotherapy in the advanced setting.

Key exclusion criteria for both phases:

History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence.
Radiotherapy with a wide field of radiation within 4 weeks prior to study treatment initiation and/or radiotherapy with a limited field of radiation for palliation within 2 weeks prior to study treatment initiation. Patients who received prior radiotherapy to ≥25% of bone marrow are not eligible independent of when it was received.
Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.
Persistent toxicities (CTCAE Grade >1) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss) after consultation with the AstraZeneca study physician.
Spinal cord compression, brain metastases or leptomeningeal metastases unless asymptomatic, treated and stable and not requiring steroids within 4 weeks prior to study treatment initiation.

Any of the following cardiac criteria at screening:

. Mean resting corrected QT interval (QTc) > 470 msec obtained from 3 consecutive ECGs
. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third-degree heart block)
. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
. Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association (NYHA) grade ≥ 2
. Uncontrolled hypotension
. Cardiac ejection fraction outside institutional range of normal or < 50% (whichever is higher)

Any of these clinically significant abnormalities of glucose metabolism at screening:

. diabetes mellitus type I or type II requiring insulin treatment
. HbA1c ≥ 8.0% (63.9 mmol/mol)
Previous allogeneic bone marrow transplant or solid organ transplant.

Key exclusion criteria for the phase III only:

Any prior treatment with SERDs, AKT, PI3K or mTOR inhibitors.
Prior treatment with CDK4/6 inhibitors in the metastatic setting (prior CDK4/6 inhibitors permitted in the adjuvant setting).

Study is for people with:

Breast Cancer

Phase:

Phase 3

Estimated Enrollment:

700

Study ID:

NCT04862663

Recruitment Status:

Recruiting

Sponsor:

AstraZeneca

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 70 Locations for this study

See Locations Near You

Research Site
Los Angeles California, 90048, United States
Research Site
San Francisco California, 94158, United States
Research Site
Aurora Colorado, 80045, United States
Research Site
Nashville Tennessee, 37203, United States
Research Site
San Antonio Texas, 78229, United States
Research Site
Darlinghurst , 2010, Australia
Research Site
Miranda , 2228, Australia
Research Site
Nedlands , 6009, Australia
Research Site
Perth , 6009, Australia
Research Site
Wahroonga , 2076, Australia
Research Site
Leuven , 3000, Belgium
Research Site
Winnipeg Manitoba, R3E 0, Canada
Research Site
Moncton New Brunswick, E1C 6, Canada
Research Site
Sault Ste. Marie Ontario, P6A 2, Canada
Research Site
Toronto Ontario, M5B 1, Canada
Research Site
Sherbrooke Quebec, J1H 5, Canada
Research Site
Chicoutimi , G7H 5, Canada
Research Site
Montreal , H3T 1, Canada
Research Site
Beijing , 10003, China
Research Site
Beijing , 10004, China
Research Site
Beijing , 10019, China
Research Site
Beijing , 10021, China
Research Site
Changchun , 13000, China
Research Site
Changsha , 41001, China
Research Site
Chengdu , 61004, China
Research Site
Chongqing , 40004, China
Research Site
Guangzhou , 51006, China
Research Site
Guangzhou , 51006, China
Research Site
Guangzhou , 51008, China
Research Site
Hangzhou , 31000, China
Research Site
Hangzhou , 31001, China
Research Site
Hangzhou , 31002, China
Research Site
Jinan , 25000, China
Research Site
Nanchang , 33000, China
Research Site
Nanchang , 33000, China
Research Site
Nanjing , 21002, China
Research Site
Nanning , 53002, China
Research Site
Shandong , , China
Research Site
Shanghai , 20003, China
Research Site
Shenyang , 11000, China
Research Site
Shenyang , 11001, China
Research Site
Urumqi , 83000, China
Research Site
Urumqi , 83000, China
Research Site
Wuhan , 43006, China
Research Site
Xi'an , 71006, China
Research Site
Xiangyang City , 44100, China
Research Site
Xian , 71010, China
Research Site
Zhengzhou , 45000, China
Research Site
Odense C , 5000, Denmark
Research Site
St Herblain , 44805, France
Research Site
Villejuif , 94805, France
Research Site
Pondicherry , 60500, India
Research Site
Chuo-ku , 104-0, Japan
Research Site
Koto-ku , 135-8, Japan
Research Site
Bydgoszcz , 85-79, Poland
Research Site
Kraków , 31-50, Poland
Research Site
Lublin , 20-09, Poland
Research Site
Warszawa , 02-78, Poland
Research Site
Warszawa , 02-78, Poland
Research Site
Barcelona , 08035, Spain
Research Site
Granada , 18014, Spain
Research Site
Lérida , 25198, Spain
Research Site
Madrid , 28040, Spain
Research Site
Madrid , 28046, Spain
Research Site
Málaga , 29010, Spain
Research Site
Pamplona , 31008, Spain
Research Site
Santiago de Compostela , 15706, Spain
Research Site
Solna , 17176, Sweden
Research Site
Bangkok , 10210, Thailand
Research Site
Bangkok , 10330, Thailand
Research Site
Bangkok , 10400, Thailand
Research Site
Bangkok , 10700, Thailand
Research Site
Chiang Mai , 50200, Thailand
Research Site
Dusit , 10300, Thailand
Research Site
Hat Yai , 90110, Thailand
Research Site
Khon Kaen , 40002, Thailand
Research Site
Ratchathewi , 10400, Thailand

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 3

Estimated Enrollment:

700

Study ID:

NCT04862663

Recruitment Status:

Recruiting

Sponsor:


AstraZeneca

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.